Advances in targeting the CD47/SIRPα “do not eat me” pathway for cancer therapy

A new editorial was recently published in Oncotarget’s Volume 15, on July 10, 2024, entitled, “The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy.”

New inhibitor drug shows promise in preventing diabetic eye and kidney disease

New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease.

February 3, 2024

Google expands AI mammography deal with iCAD

Dive Brief: Google’s health division has expanded its agreement to integrate its artificial intelligence technology into medtech company iCAD’s 2D mammography suite, about nine months

August 18, 2023

Argenx wins second FDA approval for Vyvgart in autoimmune nerve disease

After a string of clinical failures, the Dutch biotech argenx landed a much-needed win on Friday when the FDA approved its autoimmune disease drug, Vyvgart

June 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.